NASDAQ:NERV - Minerva Neurosciences, Inc.
$7.56
 $0.30
+4.13%
1:40PM EDT
2019-02-15
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson's disease. MIN-101 is a compound that blocks serotonin receptors and sigma receptors, two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-hydroxytryptamine type 1A (5-HT1A). MIN-202 is a selective orexin 2 receptor antagonist. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein, for the treatment of Parkinson's disease. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  NERV     avg for
industry  
  avg for
sector  
42 stocks weight:  38. 62   0. 00   0. 00  
42 stocks rank:  3. 06 K 1. 86 K 1. 09 K
# analyst opinions:  3. 00   14. 92   14. 43  

quick ratio:  25. 22   5. 37   1. 81  
current ratio:  26. 20   5. 69   2. 19  

target price low:  18. 00   88. 97   117. 82  
target price avg:  19. 00   115. 19   141. 96  
target price high:  20. 00   143. 40   163. 16  
1-yr high:  12. 55   124. 30   142. 77  
last close:  7. 26   101. 85   127. 84  
50-day avg:  7. 10   98. 27   122. 46  
200-day avg:  8. 63   99. 72   122. 70  
1-yr low:  5. 05   78. 19   100. 16  
volume:  134. 19 K 2. 38 M 4. 64 M
50-day avg volume:  130. 25 K 3. 31 M 4. 94 M
200-day avg volume:  175. 76 K 3. 23 M 4. 28 M

1-day return:  -0. 95 % 0. 22 % 0. 48 %
this week return:  2. 98 % 1. 77 % 2. 01 %
12-wk return:  -17. 59 % 6. 56 % 3. 33 %
52-wk return:  23. 42 % -2. 23 % 14. 35 %

enterprise value (EV):  176. 44 M 55. 17 B 104. 51 B
market cap:  283. 36 M 49. 01 B 96. 46 B
EBITDA:  -47. 62 M 4. 82 B 7. 18 B
enterprise multiple (EV/EBITDA):  -3. 71   -91. 79   2. 29  
total debt:  0. 00   13. 73 B 16. 57 B
net income (common):  -36. 81 M 2. 37 B 3. 58 B

shares outstanding:  38. 87 M 607. 99 M 1. 22 B
shares:  32. 65 M 605. 53 M 1. 15 B
shares short:  1. 23 M 11. 62 M 12. 55 M
shares short prior month:  1. 28 M 11. 95 M 13. 44 M
short ratio:  8. 23   4. 82   3. 10  
short % of float:  6. 14 % 6. 19 % 2. 82 %
total cash/share:  2. 51   12. 02   11. 46  
total cash:  97. 61 M 7. 41 B 7. 37 B
free cash flow:  -24. 64 M 95. 99 M 2. 04 B
operating cash flow:  -41. 05 M 164. 74 M 3. 04 B

book value:  2. 61   14. 43   28. 26  
price/book:  2. 78   -1. 57   -2. 97  
operating margins:  0. 00 % -458. 01 % -642. 83 %
EBITDA margins:  0. 00 % 13. 81 % 22. 47 %
profit margins:  0. 00 % 6. 57 % 9. 92 %
gross margins:  0. 00 % 49. 33 % 54. 53 %

1-yr max volatility:  13. 85 % --- ---
1-yr mean volatility:  0. 16 % 0. 01 % 0. 06 %

1-yr EPS:  -0. 95   3. 03   4. 09  
forward EPS:  -1. 51   4. 33   6. 99  
P/E:  -7. 64   6. 11   26. 91  
forward P/E:  -4. 67   8. 38   10. 48  
PE/G:  0. 77   0. 37   5. 61  
growth:  -9. 87 % 683. 72 % 104. 79 %
earnings high:  -0. 33   1. 27   1. 66  
earnings avg:  -0. 36   1. 01   1. 53  
earnings low:  -0. 38   0. 76   1. 40  
revenue high:  -0. 00   2. 86 B 11. 19 B
revenue avg:  -0. 00   2. 78 B 10. 84 B
revenue low:  -0. 00   2. 67 B 10. 64 B
return on assets:  -17. 31 % -3. 27 % 3. 81 %
return on equity:  -31. 79 % 107. 48 % 27. 82 %

beta (1yr vs S&P500):  1. 16   1. 21   0. 93  
sharpe (1yr):  0. 73   0. 06   0. 98  

held % insiders:  3. 80 % 6. 46 % 3. 21 %
held % institutions:  89. 46 % 79. 10 % 70. 01 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-14 : NERV
.    + 1.744 =         1.744 :: INITIAL WEIGHT
.  + 123.973 =       125.717 :: inverse volume-to-price addition
.  + 427.366 =       553.083 :: spline projection addition
.  - 128.492 =       424.591 :: poor performance penalty
.    x 1.296 =       550.452 :: one-year gains+dividend factor
.    x 7.465 =      4108.864 :: 13 weeks' performance factor
.    x 1.492 =      6132.433 :: industry recommendation factor
.    x 0.998 =       6121.82 :: return on assets factor
.    x 0.997 =       6102.36 :: return on equity factor
.    x 4.386 =     26763.546 :: current ratio factor
.     x 1.02 =     27310.489 :: quick ratio factor
.    x 1.059 =     28922.139 :: short ratio factor
.    x 2.028 =     58648.779 :: price-to-book factor
.    x 1.027 =     60203.867 :: 5-day avg > 50-day avg
.    x 2.126 =    128001.912 :: P/E weight
.    x 1.066 =    136445.484 :: PE/G factor
.    x 1.669 =    227689.895 :: beta factor
.    x 0.727 =    165562.486 :: sharpe factor
.    x 2.402 =    397633.508 :: target low factor
.    x 1.424 =    566183.003 :: target mean factor
.    x 1.132 =     641185.07 :: target high factor
.    x 1.066 =    683255.022 :: industry 12-weeks return
.    x 0.993 =    678467.006 :: "drift" penalty 1 days ago
.    x 0.978 =    663688.498 :: "drift" penalty 2 days ago
.      x 1.0 =    663454.165 :: overall "drift" factor
.    x 0.862 =    571591.271 :: largest single-day jump factor
.    x 0.101 =     57620.088 :: low price factor
.      x 1.0 =     57623.955 :: factor hist industry gain for week 06
.   cubeRoot =        38.625 :: reduced for readability
.                     38.625 :: FINAL WEIGHT for NASDAQ:NERV


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org